Non-secretory multiple myeloma: from biology to clinical management
- PMID: 28008276
- PMCID: PMC5171196
- DOI: 10.2147/OTT.S122241
Non-secretory multiple myeloma: from biology to clinical management
Abstract
Multiple myeloma (MM) is the second most common hematologic malignancy in the US. It is typically characterized by production of large amounts of defective immunoglobulin (Ig). Diagnosing MM and monitoring treatment response, including eventual relapse, are largely based on sequential measurements of Ig. However, a small subset of MM called non-secretory multiple myeloma (NSMM) produces no detectable Ig. This subset of true NSMM has become even smaller over time, as the advent of the serum free light chain assay has resulted in the majority of NSMM patients being recategorized as light-chain MM - that is, MM cells that produce only the light-chain component of Ig. True forms of NSMM, meaning MM that secretes no monoclonal proteins whatsoever, constitute a distinct entity that is reviewed; definition of NSMM using current detection methods, discuss the biology underpinning NSMM development, and share recommendations for how NSMM should be managed clinically with respect to detection, treatment, and monitoring.
Keywords: immunoglobulin; multiple myeloma; non-secretory.
Conflict of interest statement
Dr Tuchman reports receiving research support, honoraria and speakers’ bureau from Takeda Pharmaceuticals Inc. The authors report no further conflicts of interest in this work.
Figures


Similar articles
-
The Missing M Band: Is it Really Non Secretory Multiple Myeloma?EJIFCC. 2025 Feb 28;36(1):74-82. eCollection 2025 Mar. EJIFCC. 2025. PMID: 40061068 Free PMC article.
-
Outcome and characteristics of nonsecretory multiple myeloma compared with secretory multiple myeloma: a retrospective multicenter study from China.BMC Cancer. 2023 Oct 2;23(1):930. doi: 10.1186/s12885-023-11223-4. BMC Cancer. 2023. PMID: 37784037 Free PMC article.
-
Non-secretory Multiple Myeloma: A Report of a Rare Case.Cureus. 2025 May 8;17(5):e83759. doi: 10.7759/cureus.83759. eCollection 2025 May. Cureus. 2025. PMID: 40486389 Free PMC article.
-
Non-Secretory Myeloma: Ready for a new Definition?Mediterr J Hematol Infect Dis. 2017 Aug 18;9(1):e2017053. doi: 10.4084/MJHID.2017.053. eCollection 2017. Mediterr J Hematol Infect Dis. 2017. PMID: 28894562 Free PMC article. Review.
-
The evolving use of serum free light chain assays in haematology.Br J Haematol. 2008 May;141(4):413-22. doi: 10.1111/j.1365-2141.2008.07079.x. Epub 2008 Mar 3. Br J Haematol. 2008. PMID: 18318757 Review.
Cited by
-
Isolated Non-Secretory Extramedullary Relapse of Multiple Myeloma Responded Completely to Localized Radiotherapy.Case Rep Oncol. 2024 Mar 5;17(1):423-429. doi: 10.1159/000536675. eCollection 2024 Jan-Dec. Case Rep Oncol. 2024. PMID: 38444889 Free PMC article.
-
Beyond the mouth: Uncovering non-secretory multiple myeloma through oral symptoms.Imaging Sci Dent. 2024 Jun;54(2):211-220. doi: 10.5624/isd.20230257. Epub 2024 Apr 1. Imaging Sci Dent. 2024. PMID: 38948192 Free PMC article.
-
Circulating Tumour Cells, Cell Free DNA and Tumour-Educated Platelets as Reliable Prognostic and Management Biomarkers for the Liquid Biopsy in Multiple Myeloma.Cancers (Basel). 2022 Aug 26;14(17):4136. doi: 10.3390/cancers14174136. Cancers (Basel). 2022. PMID: 36077672 Free PMC article. Review.
-
Use of a Daratumumab-Specific Immunofixation Assay to Assess Possible Immunotherapy Interference at a Major Cancer Center: Our Experience and Recommendations.J Appl Lab Med. 2021 Nov 1;6(6):1476-1483. doi: 10.1093/jalm/jfab055. J Appl Lab Med. 2021. PMID: 34293131 Free PMC article.
-
A porcine lymphoma-derived cell line co-expressing IgM, IgG and IgA.J Vet Med Sci. 2022 Jun 10;84(6):760-765. doi: 10.1292/jvms.21-0508. Epub 2022 Apr 11. J Vet Med Sci. 2022. PMID: 35400671 Free PMC article.
References
-
- NIH Myeloma – SEER Stat Fact Sheets. [Accessed July 31, 2016]. Available from: http://seer.cancer.gov/statfacts/html/mulmy.html.
-
- Slifka MK, Ahmed R. Long-lived plasma cells: a mechanism for maintaining persistent antibody production. Curr Opin Immunol. 1998;10(3):252–258. - PubMed
-
- Mehta J, Singhal S. Hyperviscosity syndrome in plasma cell dyscrasias. Semin Thromb Hemost. 2003;29(5):467–471. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources